Featured Research

from universities, journals, and other organizations

Laying siege to chemoresistance

Date:
December 13, 2013
Source:
Elhuyar Fundazioa
Summary:
Some lymphoma types resistant to conventional therapies could be treated more effectively by using drugs geared towards the specific molecular alteration of the tumor.

To date, tests have only been carried out on cells, but a piece of research conducted by the Department of Genetics at the UPV/EHU's Faculty of Medicine in collaboration with MD Anderson and the CNIO is opening up the door for the treatment of lymphoma types that have a lower survival rate. The study of the molecular characteristics of the tumors would enable molecules that are altered in a specific way to be identified and turned into new therapeutic targets that would improve the prognosis of patients with chemoresistant lymphomata.

But there is still a long way to go. The experimental work has been done on cells. Not on mice, let alone on humans. However, a joint piece of research between the UPV/EHU-University of the Basque Country, the MD Anderson Cancer Center Madrid ―the Spanish subsidiary of the MD Anderson Cancer Center of Houston (Texas)―, and the National Centre for Oncological Research (CNIO) is suggesting that the study of gene expression in chemoresistant lymphomata could help to identify possible therapeutic targets and open up new channels of treatment.

There are still some lymphoproliferative diseases with limited therapeutic options, mainly due to the absence of targeted therapies. So although the classical Hodgkin lymphoma (HL) responds to conventional therapy based on anthracyclines (of the ABVD type) in 70 -- 80 % of cases, there is a group of patients who fail to respond, and 30 % succumb to this disease. On the other hand, peripheral T-cell lymphomata (PTCL) make up a heterogeneous and highly aggressive group for which there is currently no effective therapy. These patients are also treated with therapies based on anthracyclines (of the CHOP type), but their response is very poor: global survival depends on the PTCL subtype, but on average 70% of these patients die. So what is needed are studies that identify new therapeutic targets in refractory HL and PTCL to improve the prognosis of these patients with chemoresistant lymphomata.

So this project sought to detect the alterations that take place in these tumors and which could be targeted by drugs. The thesis "New potential therapeutic targets in conventional therapy-resistant lymphomata" (Potenciales nuevas dianas terapéuticas en linfomas resistentes a la terapia convencional), read by Esperanza Martin recently and co-supervised by África García-Orad, tenured lecturer in genetics of the UPV/EHU, and Juan Fernando García, Head of Research at MD Anderson, has submitted the initial conclusions of this research.

In each cancer alterations take place in the genes, in their structure or in their regulation. These variations are translated into modifications in the structure of specific proteins or in their quantity. These specific changes in the proteins of a specific cancer type are known as its molecular signature. Once the specific mutation of the disease or its molecular signature has been identified, a specific drug to fight these alterations can be designed. The first in this type of treatments was Imatinib. This drug is used to combat chronic myeloid leukaemia: it blocks the active centre of a protein, the kinase, the structure of which has been altered and which causes the excessive activation of the cell cycle. In the case of chemoresistant HL, histone deacetylase inhibitors (HDACi) have been identified as agents that could reverse this molecular signature. What is more, the researchers have discovered that by focusing on other molecular alterations, the effect would be boosted, thereby making it possible to determine which combination is the most suitable to treat these kinds of lymphomata that are resistant to conventional chemotherapy.

Towards personalized medicine

Although still in an experimental phase, the preliminary results of this study constitute another step forward in the field of personalized medicine. The main aim of pharmacogenetics and pharmacogenomics is to optimize the treatment of diseases on an individual level and move towards safer and more efficient personalized therapy. The recent advances in genetics and molecular biology have expanded knowledge about the biology of some tumor types enormously; this has made it possible to improve the therapeutic possibilities and expectations of these patients, a case in point has been Imatinib in chronic myeloid leukemia, one of the first examples of drugs designed on the basis of genetic studies. Another example of the advances in the effectiveness of personalized treatment is breast cancer. The detection of the genetic alteration responsible for the overexpression of the epidermal 2 growth factor, present in 20% of the cases diagnosed, makes it possible already to prescribe a specific treatment.

Pharmacogenetics and pharmacogenomics could provide knowledge to select those patients who are going to respond to treatment; this would enable the most suitable medication and/or the most appropriate dose for each patient to be selected. In other words, selecting the right drug and the right dose for each patient.


Story Source:

The above story is based on materials provided by Elhuyar Fundazioa. Note: Materials may be edited for content and length.


Cite This Page:

Elhuyar Fundazioa. "Laying siege to chemoresistance." ScienceDaily. ScienceDaily, 13 December 2013. <www.sciencedaily.com/releases/2013/12/131213135423.htm>.
Elhuyar Fundazioa. (2013, December 13). Laying siege to chemoresistance. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2013/12/131213135423.htm
Elhuyar Fundazioa. "Laying siege to chemoresistance." ScienceDaily. www.sciencedaily.com/releases/2013/12/131213135423.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) — Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) — The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) — Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins